Vivus reduce the Qsymia sales force to fifty reps With selling and administration costs of USD 22.2 million in Q2 2015 Vivus continue to have a negative operating cash flow. The reduction in field force, from 100 to 50 reps, is aimed at achieving a neutral cash flow by end of 2016. Comment: With losses of USD 49.4 million in Q2 2015 and total assets of only USD 311 million Vivus has an uncertain future. Furthermore, Qsymia was excluded from Express Scripts and CVS/Caremark formularies for 2016
|